128
17
3
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T2635 | Org 27569 | Cannabinoid Receptor | |
Org 27569, an allosteric modulator of cannabinoid CB1 receptor, can induce a CB1 receptor state that is characterized by decreased inverse agonist affinity and enhanced agonist affinity. | |||
T7375 | A-836339 | Cannabinoid Receptor | |
A-836339 acts as a potent cannabinoid receptor full agonist which has a higher affinity for the peripheral CB2 receptor (Ki = 0.64 nM) over the central CB1 receptor (Ki = 270 nM). It displays analgesic, anti-inflammatory... | |||
T7316 | LY2828360 | Cannabinoid Receptor | |
LY2828360 is a cannabinoid (CB) receptor 2 agonist (Ki = 40.3 nM). It selectively activates CB2 over CB1 in a GTPγS binding assay (EC50s = 20.1 and >100,000 nM, respectively). | |||
T1915 | AM251 | Cannabinoid Receptor , GPR | |
AM251 is a effective CB1 receptor antagonist (IC50/Ki: 8 /7.49 nM) that displays 306-fold selectivity over CB2 receptors; also effective GPR55 agonist (EC50: 39 nM). | |||
T3699 | Bay 59-3074 | Cannabinoid Receptor | |
Bay 59-3074 is a CB1/CB2 receptor partial agonist (Ki: 48.3/45.5 nM). In rat models of chronic neuropathic and inflammatory pain, it displays anti-hyperalgesic and antiallodynic properties. | |||
T4453 | JD-5037 | JD 5037 | Cannabinoid Receptor |
JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM. | |||
T28468 | PSNCBAM-1 | PSNCBAM 1 | Cannabinoid Receptor |
PSNCBAM-1 (PSNCBAM 1) is a CB1 receptor negative allosteric modulator (EC50 = 0.1 μM) with hypophagic effects in vivo. PSNCBAM-1 can be used for obesity studies. | |||
T10696 | CB2 modulator 1 | Cannabinoid Receptor | |
CB2 modulator 1 is a potent CB2 modulator. It can be used for the research for immune disorders, osteoporosis, inflammation, renal ischemia. | |||
T3530 | Otenabant | CP-945598 | Cannabinoid Receptor |
Otenabant (CP-945598) has been investigated for the treatment of Obesity. | |||
T1519L | Rimonabant | SR141716 | Cannabinoid Receptor , Antibacterial , Acyltransferase |
Rimonabant (SR141716) is an inverse agonist for the cannabinoid receptor CB1. It is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. Its main avenue of effect is a reduction in appetite. Rimonabant... | |||
T8511 | TM38837 | Cannabinoid Receptor | |
TM38837 is an antagonist of cannabinoid receptor type 1 (CB1), with potential for the treatment of obesity and type 2 diabetes. | |||
T9466 | RTICBM-189 | Others | |
RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in Ca2+ mobilization assay. RTICBM-189 has pIC50s of 5.29 and 6.25 for hCB1 and mCB1, respectivel... | |||
T8425 | Linoleoyl Ethanolamide | TRP/TRPV Channel | |
Linoleoyl Ethanolamide is an endocannabinoid agent. It acts by binding to TRPV1 increasing ERK phosphorylation and AP-1 dependent transcription in CB-receptor in an independent manner. | |||
T4654 | (±)-Ibipinabant | (±)-BMS6462,SLV319,(±)-SLV319 | Cannabinoid Receptor |
(±)-Ibipinabant ((±)-SLV319) has been used in trials studying the treatment of Obesity and Obesity and Type 2 Diabetes. | |||
T1519 | Rimonabant hydrochloride | SR 151716A,SR 141716A | Cannabinoid Receptor , Antibacterial |
Rimonabant hydrochloride (SR 141716A) is a cannabinoid receptor antagonist, binding selectively to central cannabinoid receptors (CB1) with high affinity. | |||
T14881 | CB1 antagonist 2 | AM4113 | Cannabinoid Receptor |
CB1 antagonist 2 (AM4113) is caimabinoid 1 (CB1) antagonist which inhibits CB1 in vivo with an IC50 of 25.5 nM. | |||
T12306 | OMDM-5 | Cannabinoid Receptor , Endogenous Metabolite , TRP/TRPV Channel | |
OMDM-5 is a selective anandamide cellular uptake (ACU)inhibitor(Ki of 4.8 μM). | |||
T6527 | GW842166X | Cannabinoid Receptor | |
GW842166X is a potent and highly selective agonist of cannabinoid receptor CB2 receptor with EC50 of 63 nM, shows no significant activity at CB1 receptor. Phase 2. | |||
T13289 | EHP-101 | VCE-004.8 | Cannabinoid Receptor , HIF/HIF Prolyl-Hydroxylase , PPAR |
EHP-101 (VCE-004.8) is a specific dual agonist of PPARγ and CB2 receptor with potent anti-inflammatory activity. EHP-101 attenuates adipogenesis and prevents diet-induced obesity. | |||
T2264 | AM281 | Cannabinoid Receptor | |
AM 281, a cannabinoid antagonist, reduces neurologic dysfunction and mortality rate after cecal ligation and puncture in rats. | |||
T19783 | Dehydroabiethylamine | NSC-2955,NSC 2955,Dehydroabietylamine,NSC2955,Leelamine free base,Leelamine | P450 , PDK |
Dehydroabiethylamine (NSC-2955) is an inducer of hepatic CYP2B activity. Dehydroabiethylamine inhibits pyruvate dehydrogenase kinases (PDKs) and intracellular cholesterol transport with anti-tumor activity. | |||
T1796 | Otenabant hydrochloride | Otenabant (CP-945598) HCl,CP 945598 Hydrochloride,Otenabant | Cannabinoid Receptor |
Otenabant hydrochloride (Otenabant) (CP-945598) is a competitive, high affinity, selective antagonist of the CB1 receptor (Ki: 0.7 nM). | |||
T7705 | GW 405833 | L-768242 | Cannabinoid Receptor |
GW 405833 (L-768242) is an agonist of cannabinoid-2 (CB(2)) receptor-selective | |||
T14204 | 6-Iodopravadoline | AM630 | Cannabinoid Receptor |
6-Iodopravadoline (AM630) is an antagonist of CB2 (Ki: 31.2 nM). And it shows 165-fold selectivity more than CB1 receptors. | |||
T12302 | OMDM-1 | (Z)-N-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide | Endogenous Metabolite |
OMDM-1 ((Z)-N-[(2S)-1-hydroxy-3-(4-hydroxyphenyl)propan-2-yl]octadec-9-enamide) is a selective and metabolically stable anandamide cellular uptake (ACU)inhibitor with a Ki of 2.4 μM. | |||
T6417 | BML-190 | Indomethacin morpholinylamide,IMMA,BML 190 | Cannabinoid Receptor |
BML-190 (Indomethacin morpholinylamide) is a specific CB2 receptor inverse agonist (Ki: 435 nM), with 50-fold selectivity over CB1 receptor. | |||
T5996 | CB1-IN-1 | DBPR211 | Cannabinoid Receptor |
CB1-IN-1 (DBPR211) is a peripherally restricted CB1R antagonist, for CB1R and CB2R with Ki of 0.3 nM and 21 nM,respectively. | |||
T29930 | AM-1235 | AM 1235,AM1235 | Cannabinoid Receptor |
AM-1235 is a potent and selective cannabinoid receptor CB1 agonist. | |||
T22114 | NESS 0327 | Cannabinoid Receptor | |
NESS 0327 is a high selectivity antagonist of the cannabinoid CB1 receptor. NESS 0327 is more than 60,000-fold selective for the CB1 receptor. | |||
T39024 | PrNMI | Cannabinoid Receptor | |
PrNMI is a highly effective and orally active agonist targeting the peripherally restricted cannabinoid 1 receptor (CB1R). It exhibits pronounced analgesic properties, efficiently suppressing both chemotherapy-induced pe... | |||
T79909 | AEF0117 | Cannabinoid Receptor | |
AEF0117, a signaling-specific inhibitor of cannabinoid receptor 1 (CB1-SSi), inhibits cannabinoid self-administration and behavioral disorders associated with THC, and can be used to study cannabis withdrawal. | |||
T21380 | Pravadoline | WIN 48098-6,WIN48098-6,WIN-48098-6 | Cannabinoid Receptor |
Pravadoline (WIN48098-6) is a cannabinoid receptor agonist. Pravadoline inhibited the PGs synthesis in mouse brain and displayed antinociceptive activity in rodents subjected to a variety of thermal, chemical, and mechan... | |||
T6755 | AM1241 | Cannabinoid Receptor | |
AM-1241 is a selective cannabinoid CB2 receptor agonist with Ki of 3.4 nM, exhibits 82-fold selectivity over CB1 receptor. | |||
T22009 | CB2 receptor agonist 2 | ZINC72105556,4-Quinolone-3-Carboxamide Furan CB2 Agonist | Cannabinoid Receptor |
CB2 receptor agonist 2 (ZINC72105556) is a potent and selective agonist for the CB2 (cannabinoid type 2) receptor, Ki = 8.5 nM. CB2 receptor agonist 2 has high affinity and selectivity for CB2. | |||
T30252 | AZD1940 | UNII-0J0035E9FT,AZD-1940,AZD 1940 | Cannabinoid Receptor |
AZD1940 (UNII-0J0035E9FT) is a high affinity CB(1)/CB(2) receptor agonist of the cannabinoid with oral activity. Application in the study of orofacial pain. | |||
T14302 | Olorinab | APD 371 | Cannabinoid Receptor |
Olorinab (APD 371) (APD 371) is a highly potent, selective and fully efficacious cannabinoid receptor type 2 (CB2) agonist. With an EC50 of 6.2 nM for hCB2. | |||
T9281 | (S)-2-((R)-3-(4-chlorophenyl)-N’-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-methylbutanamide | Others | |
(S)-2-((R)-3-(4-chlorophenyl)-N’-((4-chlorophenyl)sulfonyl)-4-phenyl-4,5-dihydro-1H-pyrazole-1-carboximidamido)-3-methylbutanamide is a cannabinoid receptor antagonist/inverse agonist. | |||
T36520 | COR659 | Cannabinoid Receptor , GABA Receptor | |
COR659 is a GABAB positive allosteric modulator (PAM) . COR659 suppresses alcohol and chocolate self-administration in rats[1]. COR659 apparently exerts its effects via a composite mechanism, including positive allosteri... | |||
T41350 | 6-Bromopravadoline | WIN 54461 | Cannabinoid Receptor |
6-Bromopravadoline (WIN 54461) (WIN 54461) is an antagonist of CB1. 6-Bromopravadoline acts as an inhibitor of the binding of [3H]Win 55212-2 (IC 50 =515 nM) reflective of cannabinoid receptor binding [1] [2]. | |||
T41231 | GP 1a | Cannabinoid Receptor , PERK , Arrestin | |
GP 1a is a potent agonist of cannabinoid receptor 2 (CB2) (EC50=7.1), as shown in cAMP, GTPγS and β-arrestin recruitment assays. GP 1a is approximately 30-fold more selective for CB2 receptors than CB1 receptors and incr... | |||
T37075 | CB2R PAM | Ec2la | Cannabinoid Receptor |
CB2R PAM is an orally active cannabinoid type 2 receptor (CB2Rs) positive mutational modulator that enhances CP 55940 and 2-Arachidonylglycerol-stimulated [35S]GTPγS binding to CB2 receptors, but has no effect in the abs... | |||
T67896 | CB2R/FAAH modulator-1 | Cannabinoid Receptor , FAAH | |
CB2R/FAAH modulator-1, a cannabinoid type 2 receptor (CB2R) agonist, is also a fatty acid amide hydrolase (FAAH) inhibitor (IC50=4 μM) that reduces the production of pro-inflammatory and anti-inflammatory cytokines and i... | |||
T28524 | Revosimeline | ||
Revosimeline is an agonist of cannabinoid receptor. | |||
T22539 | Abn-CBD | Others | |
GPR55 cannabinoid receptor agonist | |||
T31928 | Giminabant | ||
Giminabant is an antagonist of cannabinoid receptor antagonist (veterinary use). | |||
T26503 | AB-002 | ||
B-002 is CB (cannabinoid) receptor ligand that governs the cannabimimetic potency. | |||
T27803 | LBP-1 | LBP1 | |
LBP-1 is a cannabinoid receptor type 1 (CB1) agonist. | |||
T69062 | Nabazenil | ||
Nabazenil is a synthetic cannabinoid receptor agonist which has anticonvulsant properties. | |||
T10697 | CB2R-IN-1 | Others | |
CB2R-IN-1 is a potent inverse agonist of the cannabinoid CB2 receptor (Ki: 0.9 nM). | |||
T29929 | AM-1220 | AM 1220,AM1220 | |
AM-1220 is a potent and moderately selective agonist of the cannabinoid receptor CB1. |
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
TN2268 | Tetrahydromagnolol | Cannabinoid Receptor , GPR , GABA Receptor | |
Tetrahydromagnolol can activate cannabinoid (CB) receptors. | |||
T14011 | 2-Arachidonoylglycerol | Cannabinoid Receptor , Endogenous Metabolite | |
In the central nervous system, 2-Arachidonoylglycerol is a second endogenous cannabinoid ligand | |||
T2S0271 | Voacamine | Voacanginine | Cannabinoid Receptor , P-gp |
Voacamine (Voacanginine) is an indole alkaloid. Voacamine exhibits potent cannabinoid CB1 receptor antagonistic activity. Voacamine also inhibits P-glycoprotein (P-gp) action in multidrug-resistant tumor cells.Voacangini... | |||
TN1465 | Cannabigerol | NOS , 5-HT Receptor , ROS | |
Cannabigerol is a high affinity α±2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist ; also binds to the CB2 receptor; it can relieve interocular pressur... | |||
T13803 | N-Oleoyl glycine | Cannabinoid Receptor , Akt , Endogenous Metabolite , PPAR | |
N-Oleoyl Glycine, a Lipoamino Acid, Stimulates Adipogenesis Associated With Activation of CB1 Receptor and Akt Signaling Pathway in 3T3-L1 Adipocyte | |||
T3S0738 | Yangonin | Y100550 | Cannabinoid Receptor , NF-κB , Autophagy |
Yangonin (Y100550) is a novel CB receptor ligand, it exhibits affinity for the human recombinant CB receptor. Yangonin (Y100550) could be a valuable candidate for the intervention of NF-κB-dependent pathological conditio... | |||
TN5131 | Tetrahydrocannabivarin | THCV,delta9-Tetrahydrocannabivarin,CRM,Tetrahydrocannavarin | Cannabinoid Receptor |
Tetrahydrocannabivarin (CRM) is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile suggests therapeutic activity in ob... | |||
T3736 | Olivetol | 5-Pentylresorcinol,5-n-Amylresorcinol | Cannabinoid Receptor , P450 , IκB/IKK |
Olivetol (5-n-Amylresorcinol) (5-pentylresorcinol, 5-pentyl-1,3-benzenediol) is an organic compound found in certain species of lichen; it is also a precursor in various syntheses of tetrahydrocannabinol. Olivetol has an... | |||
T0851 | Pregnenolone | 3β-Hydroxy-5-pregnen-20-one,Arthenolone | Cannabinoid Receptor , Endogenous Metabolite , TRP/TRPV Channel , AChR , Autophagy |
Pregnenolone (Arthenolone) is an endogenous steroid hormone synthesized from cholesterol, used in the treatment of Alzheimer's disease. | |||
T9114 | β-Caryophyllene | (-)-(E)-Caryophyllene,(−)-β-caryophyllene,(−)-trans-Caryophyllene | Cannabinoid Receptor , Endogenous Metabolite |
β-Caryophyllene ((-)-(E)-Caryophyllene) acts as an CB2 receptor agonist. | |||
T14046 | Anandamide | (5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide | Cannabinoid Receptor , Endogenous Metabolite |
Anandamide ((5Z,8Z,11Z,14Z)-N-(2-Hydroxyethyl)icosa-5,8,11,14-tetraenamide), an immune modulator, acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55) in the central nervous sy... | |||
T3828 | (-)-Gallocatechin | (2S,3R)-gallocatechin,(−)-GC | Others |
(-)-Gallocatechin ((−)-GC) has free radical scavenging ability and moderate affinity to the human cannabinoid receptor. | |||
T3845 | (+)-Gallocatechin | Gallocatechol,D-Gallocatechin | Others |
(+)-Gallocatechin (Gallocatechol) possesses free radical scavenging ability. (+)-Gallocatechin has moderate affinity to the human cannabinoid receptor. | |||
TN3575 | (±)-Cannabichromene | Cannabichromene,Cannabichrome | Cannabinoid Receptor |
(±)-Cannabichromene is a major non-psychotropic phytocannabinoid that inhibits endocannabinoid inactivation and activates the transient receptor potential ankyrin-1 (TRPA1), it selectively reduces inflammation-induced hy... | |||
TC0019 | Pregnenolone acetate | 3β-Hydroxy-5-pregnen-20-one acetate | Cannabinoid Receptor , Endogenous Metabolite |
Pregnenolone acetate is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. It acts as a signaling-specific inhibitor of cannabinoid CB1 receptor, inhibits the effects of te... | |||
T11834 | Leelamine hydrochloride | Others | |
Leelamine hydrochloride, a tricyclic diterpene extracted from pine tree bark, inhibits the transcriptional activity of the androgen receptor, known to regulate fatty acid synthesis [2,3]. This compound acts as a cannabin... | |||
T16574 | Pregnenolone monosulfate sodium salt | 3β-Hydroxy-5-pregnen-20-one monosulfate sodium salt | Others |
Pregnenolone monosulfate sodium salt is a powerful neurosteroid, the main precursor of various steroid hormones including steroid ketones. Pregnenolone monosulfate sodium salt can protect the brain from cannabis intoxica... |
Cat No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-03256 | CNR1 Protein, Rat, Recombinant (His) | Rat | in vitro E. coli expression system |
G-protein coupled receptor for cannabinoids, including endocannabinoids (eCBs), such as N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG). Mediates many cannabinoid-induced effe... | |||
TMPH-01035 | CNR1 Protein-VLP, Human, Recombinant (His) | Human | HEK293 |
G-protein coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrah... | |||
TMPY-06623 | CB2/CNR2 Protein, Human, Recombinant | Human | HEK293 |
Genetic variants within the CNR2 gene encoding the cannabinoid receptor CB2 are associated with osteoporosis and low bone mineral density (BMD) in case-control studies. There is a possibility that genetic variants of the... |